Zevra Therapeutics (ZVRA) Income towards Parent Company (2014 - 2026)

Zevra Therapeutics has reported Income towards Parent Company for 13 years, with the latest figure at $37.9 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 1322.65% year-over-year to $37.9 million; the trailing twelve-month figure through Mar 2026 stood at $124.2 million (up 235.04% YoY), and the FY2025 full-year result was $83.2 million, up 178.88% from the prior year.
• Income towards Parent Company for Q1 2026 stood at $37.9 million, up from $12.2 million in the prior quarter.
• The five-year high for Income towards Parent Company was $74.7 million in Q2 2025, with the low at -$35.7 million in Q4 2024.
• Historically, Income towards Parent Company has averaged -$4.9 million across 5 years, with a median of -$10.4 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 1223.42% — and 2026, when it jumped 1322.65%.
• Zevra Therapeutics' Income towards Parent Company stood at -$35.5 million in 2022, then surged by 43.96% to -$19.9 million in 2023, then slumped by 79.67% to -$35.7 million in 2024, then soared by 134.04% to $12.2 million in 2025, then jumped by 211.47% to $37.9 million in 2026.
• The last three Income towards Parent Company figures came in at $37.9 million (Q1 2026), $12.2 million (Q4 2025), and -$544000.0 (Q3 2025), per Business Quant data.